long intergenic non-protein coding RNA 2207Genealiases: []
Q-omics provides the consensus-scored LINC02207 profile across patient tissues and cancer cell-line models. LINC02207 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC02207 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, LINC02207 RNA expression shows 13,057 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, LUAD, and UVM as cancer lineages where LINC02207 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02207 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02207 survival associations across molecular data types. LINC02207 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02207 RNA expression–survival associations across cancer types. High LINC02207 expression shows unfavorable associations in LGG, but favorable associations in BRCA, HNSC, MESO, CESC and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC02207 RNA expression.
This table summarizes LINC02207 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02207. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02207 shows lower tumor expression in LUAD, KICH, BRCA, LUSC and BLCA and higher tumor expression in KIRC. The LUAD box plot shows higher LINC02207 RNA expression in normal versus tumor tissue (log2 FC = −0.330, t-test p = .001).
This table shows molecular features associated with LINC02207 in patient tissues and cancer cell lines. In patient samples, LINC02207 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
